Simplex Trading
ONCT

Simplex Trading’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Simplex Trading’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,250
Closed -$72K – 11187
2022
Q2 		$72K Sell
3,250
-240
-7% -$5.35K ﹤0.01% 6006
2022
Q1 		$97K Buy
3,490
+3,050
+693% +$111K ﹤0.01% 6200
2021
Q4 		$19K Sell
440
-2,860
-87% -$192K ﹤0.01% 8440
2021
Q3 		$314K Hold
3,300
– – ﹤0.01% 4837
2021
Q2 		$313K Buy
3,300
+3,288
+27,400% +$390K ﹤0.01% 4911
2021
Q1 		$194K Buy
12
+9
+300% +$1.19K ﹤0.01% 4795
2020
Q4 		$28K Buy
+3
New +$190 ﹤0.01% 6731
2019
Q1 		– Hold
0
– -$2K – 8065
2018
Q4 		– Sell
-1
Closed -$200 – 6641
2018
Q3 		$17K Buy
+1
New +$2.4K ﹤0.01% 6097
2016
Q1 		– Hold
0
– -$13K – 6425
2015
Q4 		– Hold
0
– – – 3101
2015
Q3 		– Hold
0
– – – 3292
2015
Q2 		– Hold
0
– – – 3085
2015
Q1 		– Hold
0
– – – 2721
2014
Q4 		– Hold
0
– – – 2481

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Simplex Trading's ONCT Position: Q2 2023 in Review

Simplex Trading sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2023, closing a stake of 356 shares — an estimated $5K sold.

Simplex Trading first reported a position in ONCT in Q4 2014 and held it in 17 quarters. The position peaked at $319K in Q1 2021. 52 funds tracked by Wall St. Rank hold ONCT as of Q2 2023.

  • Simplex Trading reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Simplex Trading sold 356 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $5K.
  • Simplex Trading first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2014 and held it in 17 quarters.
  • Simplex Trading's Oncternal Therapeutics, Inc. Common Stock position peaked at $319K in Q1 2021.
  • 52 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Simplex Trading's 13F filing for Q2 2023, filed 4 Aug 2023.